Haldol

Haldol is the brand name for the antipsychotic medication haloperidol, supplied in oral dosage form with strength not specified in this entry. It belongs to the butyrophenone class and is marketed in the European Union as a prescription‑only product. Haloperidol works primarily as a dopamine D2 receptor antagonist and is used under medical supervision for several psychiatric conditions.

Haloperidol is prescribed for a range of psychiatric and neurological disorders where dopamine blockade is beneficial.

- Management of schizophrenia, including maintenance therapy. - Treatment of acute psychotic episodes and severe agitation. - Control of manic episodes associated with bipolar disorder. - Reduction of motor and vocal tics in Tourette syndrome. - Adjunctive therapy for severe behavioral disturbances in dementia. - Short‑term relief of hyperactivity in certain pediatric conditions.

Haloperidol may cause a variety of side effects that differ in frequency and severity.

Common: - Drowsiness or sedation. - Extrapyramidal symptoms such as tremor, rigidity, or akathisia. - Dry mouth and increased salivation. - Constipation or gastrointestinal upset. - Blurred vision or ocular discomfort. - Weight gain or appetite changes.

Serious: - Tardive dyskinesia with persistent involuntary movements. - Neuroleptic malignant syndrome, a life‑threatening reaction. - Severe hypotension or cardiac arrhythmias. - Hyperprolactinemia leading to hormonal disturbances. - Seizures in predisposed individuals. - Significant QT interval prolongation.

Before initiating haloperidol, clinicians should evaluate several safety considerations.

- Assess cardiovascular status, especially for QT prolongation risk. - Review personal or family history of movement disorders. - Monitor for signs of neuroleptic malignant syndrome during treatment. - Use caution in patients with hepatic or renal impairment. - Evaluate pregnancy and lactation status; discuss potential risks. - Adjust dose in elderly patients or those with dementia-related psychosis. - Conduct regular laboratory monitoring for electrolytes and blood glucose when indicated.

Haloperidol can interact with other medications, influencing its efficacy and safety profile.

Avoid: - Other dopamine antagonists or antipsychotics that increase extrapyramidal risk. - Medications that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution: - CNS depressants, including benzodiazepines and opioids, which may enhance sedation. - Anticholinergic agents that can mask early signs of extrapyramidal symptoms. - CYP2D6 substrates that may be affected by haloperidol metabolism. - Drugs that alter electrolyte balance, potentially worsening cardiac effects.